We are live on ! Find out more
HUMA icon

Humacyte

162 hedge funds and large institutions have $213M invested in Humacyte in 2024 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 52 increasing their positions, 38 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more capital inflows, than outflows

Capital inflows: $50.4M | Capital outflows: $21M

37% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 38

36% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 25

13% more funds holding

Funds holding: 143 → 162 (+19)

2.78% more ownership

Funds ownership: 29.94% → 32.72% (+2.8%)

44% less call options, than puts

Call options by funds: $4.41M | Put options by funds: $7.9M

Holders
162
Holders Change
+19
Holders Change %
+13.29%
% of All Funds
2.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
34
Increased
52
Reduced
38
Closed
25
Calls
$4.41​M
Puts
$7.9​M
Net Calls
-⁠$3.49​M
Net Calls Change
-⁠$229​K

HUMA Hedge Fund Activity: Q4 2024 in Review

162 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q4 2024, worth a combined $213M — up 9.3% from $195M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new HUMA positions and 25 closed out — a net gain of 9 holders — while 52 added to existing stakes and 38 trimmed.

The largest buyer was Woodline Partners, adding an estimated $9.9M. The largest seller was Voloridge Investment Management, cutting an estimated $3.76M.

  • 162 institutional investors held Humacyte (HUMA) as of Q4 2024, up from 143 in Q3 2024.
  • Funds reported $213M of Humacyte stock for Q4 2024, up 9.3% quarter-over-quarter.
  • 34 funds opened new Humacyte positions in Q4 2024 and 25 closed out, a net change of +9 holders.
  • The largest Humacyte buyer in Q4 2024 was Woodline Partners, an estimated $9.9M added.
  • The largest Humacyte seller in Q4 2024 was Voloridge Investment Management, an estimated $3.76M sold.

Based on aggregated 13F filings for Q4 2024.